Since FAK inhibition stiffens cancer cells in vitro and increased stiffness improves ICB approaches in pre-clinical studies, it is tempting to speculate that part of the beneficial effect of this combination therapy may be due to alterations in cell stiffness. This evidence concerns the gene PTK2 and cancer.